BDTX — Black Diamond Therapeutics Share News
0.000.00%
Last trade - 00:00- $108.01m
- -$2.49m
- $70.00m
Black Diamond rises on licensing deal for tumor treatment
Brief: Servier And Black Diamond Therapeutics Announce Global Licensing Agreement For BDTX-4933, A Targeted Oncology Therapy
Black Diamond Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Black Diamond Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
Black Diamond Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Black Diamond Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Black Diamond Therapeutics Announces Restructuring Plan To Focus Resources On Bdtx-1535 And Extend Cash Runway
U.S. RESEARCH ROUNDUP-Costco Wholesale, McKesson, Starbucks
U.S. RESEARCH ROUNDUP-Costco Wholesale, McKesson, Starbucks
Europe Research Roundup: Costco Wholesale, McKesson, Starbucks
Black Diamond Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Black Diamond Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview
Black Diamond Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Black Diamond Therapeutics Announces Changes To Board
U.S. RESEARCH ROUNDUP- Biomea Fusion, BlackRock, Capital Bancorp
Black Diamond Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Black Diamond Therapeutics Announces Corporate Update And Expected 2024 Milestones
Brief: Black Diamond Therapeutics Says BDTX-1535 Generally Well Tolerated, Consistent With Prior Disclosures And No New Safety Signals Observed
Brief: Black Diamond Therapeutics Q3 basic EPS USD -0.45